Dirucotide acetate    (DrugBank: Dirucotide, Acetate)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica5

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002571-16-GB
(EUCTR)
29/06/200722/02/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden
2EUCTR2004-002571-16-EE
(EUCTR)
28/09/200609/06/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
3EUCTR2004-002571-16-DK
(EUCTR)
31/05/200618/04/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
4EUCTR2004-002571-16-FI
(EUCTR)
19/04/200627/02/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
5EUCTR2004-002571-16-SE
(EUCTR)
15/08/200521/06/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden